【摘 要】
：
Endothelial integrity is a critical parameter of hemostasis, and loss of barrier function contributes to the etiology and pathogenesis of both autoimmune and infectious disease.PECAM-1 is a cellular a
【机 构】
：
Department of Hematology,Union hospital,Huazhong University of Science and Technology
论文部分内容阅读
Endothelial integrity is a critical parameter of hemostasis, and loss of barrier function contributes to the etiology and pathogenesis of both autoimmune and infectious disease.PECAM-1 is a cellular adhesion and signaling receptor comprised of six extracellular immunoglobulin (Ig)-like homology domains, a short transmembrane domain, and a 118 amino acid cytoplasmic domain that becomes serine and tyrosine phosphorylated upon activation.PECAM-1 is a major constituent of the endothelial cell intercellular junction,where up to 2 x 106 molecules concentrate upon cell-cell contact.Previous studies have shown that PECAM-1-PECAM-1 homophilic interactions mediated by N-terminal Ig domain 1 (IgD1) are required for border localization, and contribute importantly to steady-state endothelial cell barrier stability as well as the ability of the vascular endothelium to recover, both in vitro and in vivo, following inflammatory or hemostatic challenge.
其他文献
目的 白血病启动细胞(Leukemia propagating cell,LPC)是指能够在人源化小鼠体内长期重建人类白血病并具有自我更新能力的细胞,基本等同于白血病干细胞.白血病启动细胞持续存在可能是白血病耐药和复发的根源.本课题组前期通过:①人源化小鼠模型成功鉴定出Ph+ALL白血病启动细胞(CD34+CD38-CD58-) (Kong Y,et a1.Leukemia 2014);②前瞻性临
Many HDAC inhibitors have already shown remarkable antitumor activities in the clinical and preclinical settings.However, their clinical efficacy is limited because of unfavorable toxicities associate
目的 探讨CSF3R、SETBP1和SRSF2基因在慢性粒单核细胞白血病(CMML)患者中的突变情况以及这些突变与临床特征的关系.方法 对56例CMML患者的CSF3R外显子14-17、SETBP1和SRSF2基因进行测序,并且对其临床特征进行研究.结果 在56例患者CMML中,14例(14/56,25％)患者具有SRSF2突变,4例(4/56,7.1％)具有CSF3R突变,3例(3/56,5.3
What do we know about allo HSCT?Are these data reflecling present time?1982 to 2006 Median age:35-39 years HLA-ID siblings CYTBI/BUCY Evidence based medicine=Not always real life CDT is a major factor
目的 免疫性血小板减少性紫癜(Immune thrombocytopenia,ITP)是以血小板破坏过多和生成不足为特征的自身免疫性出血性疾病.骨髓是巨核细胞发育成熟和血小板生成的场所,已有体外实验及小鼠实验证实骨髓内免疫细胞以及内皮祖细胞和血管周围细胞会影响巨核细胞的正常发育和血小板的生成,但是目前尚未有报道ITP患者体内骨髓微环境是否存在异常.因此,本研究旨在评估ITP患者骨髓免疫微环境和血管
Background Thrombocytopaenia is a frequent complication of liver cirrhosis, and ITP is closely related with H.pylori.Several studies illuminate the associations between H.pylori and viral hepatitis, b
目的 探索盐酸替罗非班对apoe-/-小鼠体内血小板CD40L表达和调节性T细胞(Treg)含量的影响及最终对动脉粥样硬化斑块的作用。方法 6周龄雄性apoe-/-小鼠随机分为4组,每组8只,分别为对照组,高脂组,阿托伐他汀组,替罗非班组。喂养16周后,流式细胞仪检测血小板表面CD62P, JON/A和CD40L表达以及外周血单核细胞中Treg比例。血小板聚集仪检测血小板聚集率。苏木精-伊红染色(
研究背景免疫性血小板减少症(ITP)是一种获得性自身免疫性出血疾病,约占临床出血性疾病的1/3皮肤粘膜、内脏甚至颅内出血,出血风险随年龄增加,严重者可能危及生命慢性ITP患者生活质量低于癌症患者ITP发病率ITP的发病机制—血小板破坏增多ITP的发病机制 —血小板破坏增多
ARC综合症(arthrogryposis-renal dysfunction-cholestasis,ARC)是一种常染色体隐性遗传性疾病,表现为关节挛缩、肾功能衰竭、胆汁淤滞以及血小板α-颗粒内容物的缺失,研究表明Vps33b基因突变是导致这个疾病发生的分子机制之一,因此我们推测Vps33b蛋白可能参与了α-颗粒的形成。
研究目的 血小板衍生生长因子(Platelet-derived growth factor, PDGF)是人体内一种重要的生长因子.它的受体(PDGF receptor, PDGFR)是酪氨酸激酶家族成员之一.我们前期的研究已经证实了PDGF/PDGFR通路在巨核细胞/血小板生成过程中有重要作用.本项目旨在研究PDGF/PDGFR于原发性血小板增多症发病中的作用,并探索针对其机制的治疗方法.